Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Abd-Elsalam, 2020
 
NCT04353336
RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
97/97 inconclusive
    ARCHAIC -hydroxychloroquine, 2020
     
    NL8490
    RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
    9/6 inconclusive
      CCAP-1, 2020
       
      NCT04345289
      RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
      -/- inconclusive
        Chen, 2020
         
        NCT04384380
        RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
        21/12 inconclusive
          Duke university HCQ, 2020
           
          NCT04335552
          RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
          4/2 no results
            discontinued, found in Axfors et al. meta-analysis
            NO COVID-19 (Lyngbakken), 2020
             
            NCT04316377
            RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
            27/26 inconclusive
              OAHU-COVID19, 2020
               
              NCT04345692
              RCThydroxychloroquinestandard of careCOVID 19 hospitalizedNA
              10/6 inconclusive
                RECOVERY, 2020
                 
                NCT04381936
                RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                1561/3155 safety concern
                • inconclusive 9 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                • statistically significant 14 % increase in death or ventilation with a moderate degree of certainty due to some concern in risk of bias
                SOLIDARITY (WHO study) HCQ, 2020
                 
                NCT04315948
                RCThydroxychloroquinestandard of careCOVID 19 hospitalizedsome concern
                947/906 inconclusive
                • inconclusive 19 % increase in deaths,deaths (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
                Tang, 2020
                 
                ChiCTR2000029868
                RCThydroxychloroquinestandard of careCOVID 19 hospitalizedhigh
                75/75 safety concern
                • statistically significant 3.5-fold increase in adverse events but with a low degree of certainty due to high risk of bias
                Paccoud, 2020 OBShydroxychloroquinestandard of careCOVID 19 hospitalizedserious
                38/46 inconclusive

                  COVID 19 all comers meta-analysis

                  ChiCTR2000030054-HCQ (Chen), 2020
                   
                  ChiCTR2000030054
                  RCThydroxychloroquinestandard of careCOVID 19 all comershigh
                  18/12 inconclusive

                    COVID-19 mild to moderate meta-analysis

                    Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020
                     
                    NCT04322123
                    RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                    221/227 safety concern
                    • statistically significant 74 % increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
                    HC-nCoV (Shanghai), 2020
                     
                    NCT04261517
                    RCThydroxychloroquinestandard of careCOVID-19 mild to moderatesome concern
                    15/15 inconclusive
                      Zhaowei Chen, 2020
                       
                      ChiCTR2000029559
                      RCThydroxychloroquinestandard of careCOVID-19 mild to moderatehigh
                      31/31 suggested
                      • suggested 2.4-fold increase in clinical improvement but with a low degree of certainty due to high risk of bias
                      • suggested 2.4-fold increase in radiologic improvement (7-day) but with a low degree of certainty due to high risk of bias

                      COVID-19 severe or critically meta-analysis

                      REMAP-CAP-HCQ, 2020
                       
                      NCT02735707
                      RCThydroxychloroquinestandard of careCOVID-19 severe or criticallyNA
                      61/81 inconclusive
                      • inconclusive 4 % increase in deaths (PE)
                      REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia.multi-arm study
                      Mahevas, 2020 OBShydroxychloroquinestandard of careCOVID-19 severe or criticallyserious
                      84/97 inconclusive

                        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).